Hypertension drug developer Retension (RTSN.US) applies for U.S. listing, plans to raise $58 million.

U.S. hypertension drug developer Retension Pharmaceuticals filed with the U.S. Securities and Exchange Commission (SEC) on Friday to raise up to $58 million through an initial public offering (IPO). The company had previously submitted its listing application confidentially on December 31, 2025. It plans to list on the Nasdaq under the ticker symbol "RTSN," and has not yet disclosed the pricing terms of its IPO. Retension Pharmaceuticals, founded in 2023, is a clinical-stage biopharmaceutical company currently focused on developing a single product, RTN-001. This is a once-daily oral PDE-5 inhibitor for the treatment of uncontrolled hypertension and resistant hypertension. First-generation PDE-5 inhibitors (such as Viagra) have never been able to achieve meaningful blood pressure reduction. The company believes this is because such drugs struggle to adequately penetrate the smooth muscle-rich central vasculature, whereas RTN-001 has been redesigned to improve bioavailability and increase its distribution in these tissues. The drug was originally developed by Surface Logix, then passed successively through Nano Terra, Kadmon, and Sanofi, until the current team re-licensed it in 2023, bringing with it data from nine completed trials, including two Phase 2 trials. The company launched a 280-patient Phase 2b dose-finding trial in October 2025, with approximately 40% of patients currently enrolled, and expects to report preliminary data in the first half of 2027.